220652-02-8

Basic information

• Product Name: Carbamic acid, [[[(1,1-dimethylethoxy)carbonyl]imino](methylthio)methyl](phenylmethyl)-, 1,1-dimethylethyl ester
• CAS NO: 220652-02-8
• Molecular Formula: C19H28N2O4S
• Molecular Weight: 380.508
• Mol File: 220652-02-8.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [[[(1,1-dimethylethoxy)carbonyl]imino](methylthio)methyl](phenylmethyl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [[[(1,1-dimethylethoxy)carbonyl]imino](methylthio)methyl](phenylmethyl)-, 1,1-dimethylethyl ester(220652-02-8)
• EPA Substance Registry System: Carbamic acid, [[[(1,1-dimethylethoxy)carbonyl]imino](methylthio)methyl](phenylmethyl)-, 1,1-dimethylethyl ester(220652-02-8)

Safety Data

• Hazardous Substances Data: 220652-02-8(Hazardous Substances Data)

Upstream product

• 322474-21-5 N,N'-bis-Boc-S-methyl-isothiourea 
• 100-51-6 benzyl alcohol 
• 100-39-0 benzyl bromide 
• 107819-90-9 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 641611-38-3 17-cyclopropylmethyl-6,7-didehydro-4,5α-epoxy-5'-bis-tert-butoxycarbonyl-(N'-benzyl)guanidinyl-3,14-dihydroxyindolo[2',3':6,7]morphinan 
• 641611-17-8 17-cyclopropylmethyl-6,7-didehydro-4,5α-epoxy-5'-bis-tert-butoxycarbonyl-(N'-benzyl)guanidinylethyl-3,14-dihydroxyindolo[2',3':6,7]morphinan 
• 1176238-50-8 2,6-[(di-tert-butoxycarbonyl)diimido]-3-benzyl-5-tert-butoxycarbonyl-1,3,5,7,16-pentaazacyclotetracosan-4-one 
• 1176817-96-1 1-amino-17-(N₁,N₂-bis(tert-butoxycarbonyl)-N₁-(benzyl)guanidine)-9-azaheptadecane 
• 1334182-28-3 C₆₆H₇₉N₁₁O₁₀ 

Relevant articles and documents

A convenient synthesis of disubstituted guanidines via the Mitsunobu protocol

An efficient synthetic method for the preparation of disubstituted guanidines is described. Primary and secondary alcohols were treated with guanylating agents under Mitsunobu conditions and their subsequent reactions with amines provided disubstituted guanidines.

Design, synthesis, and: In vitro and in vivo characterization of 1-{4-[4-(substituted)piperazin-1-yl]butyl}guanidines and their piperidine analogues as histamine H3 receptor antagonists

Previously, we have shown that 1-substituted-[4-(7-phenoxyheptylpiperazin-1-yl)butyl]guanidine with electron withdrawing substituents at position 4 in the benzyl moiety exhibits high in vitro affinities toward the guinea pig jejunal histamine H3/sub

Development of a peptidomimetic antagonist of neuropeptide FF receptors for the prevention of opioid-induced hyperalgesia

Through the development of a new class of unnatural ornithine derivatives as bioisosteres of arginine, we have designed an orally active peptidomimetic antagonist of neuropeptide FF receptors (NPFFR). Systemic low-dose administration of this compound to rats blocked opioid-induced hyperalgesia, without any apparent side-effects. Interestingly, we also observed that this compound potentiated opioid-induced analgesia. This unnatural ornithine derivative provides a novel therapeutic approach for both improving analgesia and reducing hyperalgesia induced by opioids in patients being treated for chronic pain.